Sagimet Biosciences Inc. Series A Common Stock (SGMT NASDAQ) stock market data APIs
$10.5959
-1.17(-11%)
as of August 14, 2026
Try our APIs with
free plan!
Sagimet Biosciences Inc. Series A Common Stock Financial Data Overview
Price chart is built with
Anychart
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Prev. Close
10.5959
Open
9.4275
High
10.6051
Low
9.1065
52 wk Range
4.5-10.6
Market Cap
656 M
Shares Outstanding
61 591 K
EPS
-0.26
Beta
3.399
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Sagimet Biosciences Inc. Series A Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Sagimet Biosciences Inc. Series A Common Stock data using free add-ons & libraries
Get Sagimet Biosciences Inc. Series A Common Stock Fundamental Data
Sagimet Biosciences Inc. Series A Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Sagimet Biosciences Inc. Series A Common Stock Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-11
- EPS/Forecast: -0.28
Get Sagimet Biosciences Inc. Series A Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sagimet Biosciences Inc. Series A Common Stock News
New
Sagimet Biosciences GAAP EPS of -$0.26 in-line
* Sagimet Biosciences press release [https://seekingalpha.com/pr/20614354-sagimet-biosciences-reports-second-quarter-2026-financial-results-and-provides-corporate] (SGMT [https://seekingalpha.com/sy...
Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
FOSTER CITY, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional meta...
Sagimet Biosciences (SGMT) Attracts Attention After Russel Indexes Inclusion
Sagimet Biosciences Inc. (NASDAQ:SGMT) is one of the 10 best stocks under $10 that could triple. On June 29, Sagimet Biosciences Inc. (NASDAQ:SGMT) announced that it had been included in the broader ...
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN MATEO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabol...
Get Sagimet Biosciences Inc. Series A Common Stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
